BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Given the effectiveness of poly(ADP-ribose) polymerase inhibitors (PARPi) in HRD-related cancers such as BRCA1/BRCA2-mutated breast and ovarian cancers, this study suggests PARPi as a potential treatment for EC.4